---
title: "Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294684905.md"
description: "Opus Genetics has completed patient enrollment in its registrational Phase 3 trial for OPGx-LCA5, a gene therapy targeting LCA5-associated Inherited Retinal Disease. The company reached the designated participant capacity, marking a significant milestone. This completion paves the way for the next trial phase, which will evaluate the treatment's efficacy and safety for this rare genetic condition."
datetime: "2026-08-03T11:03:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294684905.md)
  - [en](https://longbridge.com/en/news/294684905.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294684905.md)
generator: "portal-rs"
---

# Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics has successfully finished enrolling patients for the registrational Phase 3 trial of OPGx-LCA5 to treat LCA5-linked Inherited Retinal Disease. This major milestone marks the completion of patient recruitment for the trial, bringing the total number of participants to the designated capacity required for the study. OPGx-LCA5 aims to offer a revolutionary treatment option for individuals affected by LCA5-associated Inherited Retinal Disease, addressing an unmet medical need. The completion of patient enrollment sets the stage for the next phase of the trial, which will assess the efficacy and safety of OPGx-LCA5 in treating this rare genetic condition.

### Related Stocks

- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)

## Related News & Research

- [Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease](https://longbridge.com/en/news/294682847.md)
- [Brokers Set Expectations for Opus Genetics FY2030 Earnings](https://longbridge.com/en/news/295653446.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Genetix kicks off sickle cell disease awareness campaign](https://longbridge.com/en/news/296468544.md)
- [Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands](https://longbridge.com/en/news/296027938.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**